Literature DB >> 24631146

Impact of planning target volume margins and rectal distention on biochemical failure in image-guided radiotherapy of prostate cancer.

Benedikt Engels1, Guy Soete2, Thierry Gevaert2, Guy Storme2, Dirk Michielsen3, Mark De Ridder2.   

Abstract

BACKGROUND AND
PURPOSE: A previous study in our department demonstrated the negative impact on freedom from biochemical failure (FFBF) of using too narrow planning target volume (PTV) margins during prostate image-guided radiotherapy (IGRT). Here, we investigated the impact of appropriate PTV margins and rectal distention on FFBF. METHODS AND MATERIALS: A total of 50 T1-T3N0M0 prostate cancer patients were treated with daily IGRT by implanted markers. In the first 25 patients, PTV margins were 3mm laterolateral, 5mm anterioposterior and 4mm craniocaudal. The subsequent 25 patients were treated with isotropic margins of 6mm. The rectal cross-sectional area (CSA) was determined on the planning CT. Median follow-up was 61months.
RESULTS: The overall 5-year FFBF was 83%. A 6mm PTV margin was related to increased 5-year FFBF on univariate analysis (96% vs 74% with the tighter PTV margins, p=0.04). The 5-year FFBF of patients with a rectal distention on the planning CT was worse compared to those with limited rectal filling (75% for CSA⩾9cm(2) vs 89% for CSA<9cm(2), p=0.02), which remained significant on multivariate analysis (p=0.04).
CONCLUSION: This retrospective study illustrated the positive impact of PTV margin adaptation and addressed the importance of avoiding rectal distention at time of the planning CT.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Biochemical failure; Image-guided radiotherapy; Prostate cancer; Rectal distention

Mesh:

Year:  2014        PMID: 24631146     DOI: 10.1016/j.radonc.2014.02.009

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  13 in total

1.  Moderate hypofractionation and simultaneous integrated boost by helical tomotherapy in prostate cancer: monoinstitutional report of acute tolerability assessment with different toxicity scales.

Authors:  Giuseppe Ferrera; Gianluca Mortellaro; Mariella Mannino; Giovanni Caminiti; Antonio Spera; Vanessa Figlia; Giuseppina Iacoviello; Gioacchino Di Paola; Rosario Mazzola; Antonio Lo Casto; Filippo Alongi; Maria Pia Pappalardo; Roberto Lagalla
Journal:  Radiol Med       Date:  2015-05-24       Impact factor: 3.469

2.  Decreased acute toxicities of intensity-modulated radiation therapy for localized prostate cancer with prostate-based versus bone-based image guidance.

Authors:  Kiyonao Nakamura; Takashi Mizowaki; Haruo Inokuchi; Itaru Ikeda; Takahiro Inoue; Tomomi Kamba; Osamu Ogawa; Masahiro Hiraoka
Journal:  Int J Clin Oncol       Date:  2017-07-29       Impact factor: 3.402

Review 3.  Radiation oncology in the era of precision medicine.

Authors:  Michael Baumann; Mechthild Krause; Jens Overgaard; Jürgen Debus; Søren M Bentzen; Juliane Daartz; Christian Richter; Daniel Zips; Thomas Bortfeld
Journal:  Nat Rev Cancer       Date:  2016-03-18       Impact factor: 60.716

4.  Dosimetric implications of inter- and intrafractional prostate positioning errors during tomotherapy : Comparison of gold marker-based registrations with native MVCT.

Authors:  Peter Wust; Marc Joswig; Reinhold Graf; Dirk Böhmer; Marcus Beck; Thomasz Barelkowski; Volker Budach; Pirus Ghadjar
Journal:  Strahlenther Onkol       Date:  2017-05-02       Impact factor: 3.621

5.  Image registration assessment in radiotherapy image guidance based on control chart monitoring.

Authors:  Wenyao Xia; Stephen L Breen
Journal:  J Med Imaging (Bellingham)       Date:  2018-03-14

6.  Magnetic resonance imaging-guided radiotherapy for intermediate- and high-risk prostate cancer: Trade-off between planning target volume margin and online plan adaption.

Authors:  Shyama U Tetar; Anna M E Bruynzeel; Lisa Verweij; Omar Bohoudi; Berend J Slotman; Tezontl Rosario; Miguel A Palacios; Frank J Lagerwaard
Journal:  Phys Imaging Radiat Oncol       Date:  2022-07-03

7.  Low incidence of late recurrence in patients with intermediate-risk prostate cancer treated by intensity-modulated radiation therapy plus short-term androgen deprivation therapy.

Authors:  Rihito Aizawa; Kenji Takayama; Kiyonao Nakamura; Takahiro Inoue; Toshinari Yamasaki; Takashi Kobayashi; Shusuke Akamatsu; Osamu Ogawa; Takashi Mizowaki
Journal:  Int J Clin Oncol       Date:  2019-12-09       Impact factor: 3.402

8.  What benefit could be derived from on-line adaptive prostate radiotherapy using rectal diameter as a predictor of motion?

Authors:  Richard Oates; Suki Gill; Farshad Foroudi; Michael Lim Joon; Michal Schneider; Mathias Bressel; Tomas Kron
Journal:  J Med Phys       Date:  2015 Jan-Mar

Review 9.  ACR Appropriateness Criteria for external beam radiation therapy treatment planning for clinically localized prostate cancer, part II of II.

Authors:  Nicholas G Zaorsky; Timothy N Showalter; Gary A Ezzell; Paul L Nguyen; Dean G Assimos; Anthony V D'Amico; Alexander R Gottschalk; Gary S Gustafson; Sameer R Keole; Stanley L Liauw; Shane Lloyd; Patrick W McLaughlin; Benjamin Movsas; Bradley R Prestidge; Al V Taira; Neha Vapiwala; Brian J Davis
Journal:  Adv Radiat Oncol       Date:  2017-03-20

10.  A novel CBCT-based method for derivation of CTV-PTV margins for prostate and pelvic lymph nodes treated with stereotactic ablative radiotherapy.

Authors:  Ciara A Lyons; Raymond B King; Sarah O S Osman; Stephen J McMahon; Joe M O'Sullivan; Alan R Hounsell; Suneil Jain; Conor K McGarry
Journal:  Radiat Oncol       Date:  2017-08-04       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.